Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Pulmonary Hypertension, September 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 135 articles: HTML format

Single Articles

1. GUEVARA YAS, Gonzaga-Costa K, Calixto GL, Diaz LC, et al
   Therapeutic effects of trans-3-methoxy-beta-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension.
   Eur J Pharmacol. 2026 Sep 4:179310. doi: 10.1016/j.ejphar.2026.179310.
   PubMed    
   Abstract available
   
   

2. LI Z, Xu X, Li J, Fang Y, et al
   Artificial Intelligence in Pulmonary Hypertension: Current State and Future Prospects.
   Rev Cardiovasc Med. 2026;27:48114.
   PubMed    
   Abstract available
   
   

3. EL KAISSI J, Laoutid J
   Continuous Spinal Anesthesia in a High-Risk Patient With Pulmonary Hypertension Undergoing Hip Fracture Repair: A Case Report.
   Case Rep Anesthesiol. 2026;2026:5262622.
   PubMed    
   Abstract available
   
   

4. HAN DS, Wei MM, Liu RX, Ma YG, et al
   [Effects of Gualou Xiebai Banxia Decoction on pulmonary vascular remodeling in rats with hypoxic pulmonary hypertension].
   Zhongguo Zhong Yao Za Zhi. 2026;51:4723-4733.
   PubMed    
   Abstract available
   
   

5. CANTOR HJ, Zhu D, Li Z, Hu S, et al
   Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes.
   ACS Nano. 2026;20:23871-23883.
   PubMed    
   Abstract available
   
   

6. HENEMA MMF, Brown SC, Smit FE, Botes L, et al
   An analysis of imaging modalities to assess the right and left heart in pulmonary hypertension with left-to-right shunts.
   Cardiovasc J Afr. 2026;37:345-353.
   PubMed    
   Abstract available
   
   

7. AVERJANOVAITE V, Gumbiene L, Zakarkaite D, Laukyte-Sleniene M, et al
   Pulmonary Function and Exercise-Based Assessments for the Detection of Pulmonary Hypertension in Fibrotic Interstitial Lung Disease.
   Pulm Circ. 2026;16:e70402.
   PubMed    
   Abstract available
   
   

8. NISHIYAMA M, Okada T, Teranaka W, Naruko T, et al
   Chronic thromboembolic pulmonary hypertension: towards an etiology-oriented conceptual framework.
   Front Med (Lausanne). 2026;13:1910552.
   PubMed    
   Abstract available
   
   

9. WU M, Su H, Sun X, Gong S, et al
   Diffusing Capacity of the Lung for Carbon Monoxide and the Risk of All-Cause Mortality in Patients With Pulmonary Hypertension Caused by Fibrosing Mediastinitis: A Multicenter Cohort Study.
   Pulm Circ. 2026;16:e70401.
   PubMed    
   Abstract available
   
   

10. WICK C, Lichtblau M, Titz A, Muller J, et al
    Effect of low-flow oxygen therapy on 6 minute walk test in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomized non-inferiority crossover trial.
    Eur Heart J Open. 2026;6:oeag125.
    PubMed    
    Abstract available
    
    

11. LUO L, Wang X, Huang K, Yang Y, et al
    Anomalous origin of the left coronary artery from the pulmonary artery with coronary artery fistula in an adult presenting with cardiomegaly, abnormal electrocardiogram, myocardial perfusion defect and pulmonary hypertension: a case report.
    Front Cardiovasc Med. 2026;13:1844272.
    PubMed    
    Abstract available
    
    

12. SUN Y, Ding R, Su X, Qin L, et al
    Pulmonary Hypertension Molecular Switch: HIF Signaling Pathway.
    Pulm Circ. 2026;16:e70385.
    PubMed    
    Abstract available
    
    

13. YAKU A, Mylvaganam RJ, Shah SJ
    Redefining systemic sclerosis-associated pulmonary hypertension as an immune-mediated vasculopathy across the cardiopulmonary circulation.
    Curr Opin Rheumatol. 2026 Sep 3. doi: 10.1097/BOR.0000000000001202.
    PubMed    
    Abstract available
    
    

14. COSTELLE A, Leewiwatwong S, Mugler JP 3rd, Mummy D, et al
    Standardized Spectral Mapping With (129)Xe Chemical Shift Imaging: Investigating Red Blood Cell Shift Heterogeneity in Pulmonary Hypertension.
    NMR Biomed. 2026;39:e70388.
    PubMed    
    Abstract available
    
    

15. HOU P, Ke M, Jiang Q, Lai N, et al
    Cerebral hypoperfusion in pulmonary arterial hypertension: Association with right ventricular dysfunction and risk stratification.
    Ther Adv Respir Dis. 2026;20:17534666261485141.
    PubMed    
    Abstract available
    
    

16. BIKOU O, Halouani A, Sun Y, Bisserier M, et al
    MicroRNA-224 orchestrates BMP and TGFbeta signaling and is a therapeutic target in preclinical pulmonary arterial hypertension.
    Sci Transl Med. 2026;18:eaef6676.
    PubMed    
    Abstract available
    
    

17. YE P, Zhu L, Chu P, Wang D, et al
    Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1.
    Biochem Genet. 2026 Sep 2. doi: 10.1007/s10528-026-11446.
    PubMed    
    Abstract available
    
    

18. ZOU Y, Ahmad A, Zhang S, Wang Y, et al
    Repurposing SGLT2 inhibitors in pulmonary arterial hypertension: A multi-center longitudinal pilot study demonstrating favorable effects on risk profile and ventricular coupling.
    Ther Adv Respir Dis. 2026;20:17534666261479969.
    PubMed    
    Abstract available
    
    

19. CHANGELA S, Hadidchi R, Madan J, Henry SS, et al
    Elevated risk of first-time pulmonary hypertension among COVID-19 survivors: a 4.5-year longitudinal study.
    ERJ Open Res. 2026;12:01768-2025.
    PubMed    
    Abstract available
    
    

20. LI Y, Huang J, Zhang X, Liu Y, et al
    Internet-Based home care education for children with pulmonary hypertension: a public health perspective.
    Front Pediatr. 2026;14:1759723.
    PubMed    
    Abstract available
    
    

21. SAWCZAK F, Kukfisz A, Dudek M, Straburzynska-Migaj E, et al
    Relationship between right heart catheterization and exercise testing in heart failure patients with and without pulmonary hypertension - cross-sectional study.
    Front Cardiovasc Med. 2026;13:1812393.
    PubMed    
    Abstract available
    
    

22. LU GF, Guo Y, Geng F
    Circular RNAs regulate the progression of pulmonary hypertension through distinct roles and mechanisms.
    J Pharmacol Exp Ther. 2026;393:104987.
    PubMed    
    Abstract available
    
    

23. KRUTHOF J, De Haes J
    Changing paradigm in pulmonary hypertension during pregnancy: from universal contraindication to individualized management.
    Int J Obstet Anesth. 2026;68:105272.
    PubMed    
    
    
    

24. JIANG S, Tian L, Qu J, Hong Y, et al
    Human iPSC-Derived Vascularised Lung Organoids for Modelling COPD and Pulmonary Hypertension.
    Cell Prolif. 2026 Sep 1:e70273. doi: 10.1111/cpr.70273.
    PubMed    
    Abstract available
    
    

25. MILANOVA-ILIEVA D, Ketev K, Karavelikova I, Chochkova-Bukova L, et al
    Long-term management of a child with aortopulmonary septal defect and Eisenmenger syndrome: a 6-year follow-up case study.
    Folia Med (Plovdiv). 2026;68.
    PubMed    
    Abstract available
    
    

26. LI W, Ke X, Ma J, Jin R, et al
    Patients' perspectives on pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study.
    Front Public Health. 2026;14:1869309.
    PubMed    
    Abstract available
    
    

27. KIM NY, Im DJ, Hong YJ, Lee JW, et al
    Sequential Changes in Right Ventricular Straein During the Development of Pulmonary Hypertension Assessed With Magnetic Resonance Feature Tracking: An Animal Study.
    Korean J Radiol. 2026 Sep 1. doi: 10.3348/kjr.2026.0774.
    PubMed    
    Abstract available
    
    

28. MADONNA R, Del Boccio P, Borghini A, Alberti M, et al
    Sodium-glucose cotransporter 2 inhibitors are associated with reduced circulating activin A and modulation of BMP/activin signaling in ischemic cardiomyopathy with high echocardiographic probability of pulmonary hypertension.
    Geroscience. 2026 Aug 31. doi: 10.1007/s11357-026-02497.
    PubMed    
    Abstract available
    
    

29. CHEN W, Dong Y, Shi Q, Meng H, et al
    Multi-omics and experimental validation reveal the proliferative mechanism of ACSL4 in pulmonary hypertension and identify potential FDA-approved drugs via in silico screening.
    Vascul Pharmacol. 2026;164:107694.
    PubMed    
    Abstract available
    
    

30. LI X, Wu L, Liu X, Li P, et al
    Warfarin Dose Adjustment During Rifampicin Therapy: A Case Report with Practical Monitoring Implications.
    J Vis Exp. 2026;.
    PubMed    
    Abstract available
    
    

31. ZHUANG S, Zheng L, Wang X, Pu J, et al
    The clinical characteristics and risk factors of pulmonary arterial hypertension in primary Sjogren disease: a single-center retrospective study.
    Clin Rheumatol. 2026;45:5615-5624.
    PubMed    
    Abstract available
    
    

32. PARK HW, Park Y, Lee JJ, Ju JH, et al
    Clinical characteristics and factors associated with progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease.
    Clin Rheumatol. 2026;45:5585-5595.
    PubMed    
    Abstract available
    
    

33. MOURA-FERREIRA S, Milani M, Dhont S, L'Hoyes W, et al
    Risk stratification in aortic stenosis: exercise haemodynamics to refine risk in early cardiac damage stages.
    Eur Heart J Cardiovasc Imaging. 2026;27:1686-1698.
    PubMed    
    Abstract available
    
    

34. TEIXEIRA M, Couto DS, Oliveira MI, Aires I, et al
    Transpulmonary proteomic gradient analysis in women with pulmonary arterial hypertension associated with systemic sclerosis.
    J Proteomics. 2026;331:105703.
    PubMed    
    Abstract available
    
    

35. BARBERO C, Loforte A, Scala V, Trompeo AC, et al
    Emergent simultaneous cesarean section and maternal cardiac surgery.
    Heart Lung. 2026;79:102820.
    PubMed    
    Abstract available
    
    

36. GOWDA N, Lal Negi S, Puri GD, Kumar R, et al
    Net Atrioventricular Compliance: A Determinant of Pulmonary Artery Pressure in Patients Undergoing Mitral Valve Replacement for Severe Mitral Stenosis.
    Semin Cardiothorac Vasc Anesth. 2026;30:183-190.
    PubMed    
    Abstract available
    
    

37. KADOTA M, Yagi S, Akagi S, Kasahara S, et al
    Treat-and-repair Strategy for Atrial Septal Defect with Eisenmenger Syndrome due to Pulmonary Arterial Hypertension.
    Intern Med. 2026;65:2346-2351.
    PubMed    
    Abstract available
    
    

38. AL-QAZAZI R, Emon IM, Potus F, Martin AY, et al
    Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension.
    Eur Heart J. 2025 Aug 29:ehaf611. doi: 10.1093.
    PubMed    
    Abstract available
    
    

39. WANG X, Qiu F, Li S, Li S, et al
    Cross-sectional independent associations of anxiety and depressive symptoms with cardiopulmonary exercise performance in treatment-naive chronic thromboembolic pulmonary hypertension.
    J Psychosom Res. 2026;211:112993.
    PubMed    
    Abstract available
    
    

40. DONG Z, Lu Q, Xue Z, Li Y, et al
    Sodium tanshinone IIA sulfonate attenuates pulmonary vascular remodeling by targeting DYRK1A in pulmonary hypertension.
    Phytomedicine. 2026;162:158794.
    PubMed    
    Abstract available
    
    

41. BEKIARIDOU A, Mughrabi I, Rios N, Giannakoulas G, et al
    Splenic Focused Ultrasound Improves Experimental Pulmonary Hypertension and Reprograms Immune Responses in Female and Male Rats.
    Pulm Circ. 2026;16:e70392.
    PubMed    
    Abstract available
    
    

42. CHEN R, Bagherzadeh SP, Patel N, Khoury P, et al
    Validation of Tricuspid Annular Displacement by Tissue Doppler in Pulmonary Hypertension.
    Pulm Circ. 2026;16:e70372.
    PubMed    
    Abstract available
    
    

43. HALL MM, Rinne ST, Elwy AR, Wiener RS, et al
    Quality of Pulmonary Hypertension Care Within Expert PH Centers: Patient and Provider Perspectives From a Multi-Site Qualitative Study.
    Pulm Circ. 2026;16:e70408.
    PubMed    
    Abstract available
    
    

44. FOULI GE, Subba-Rao R, Bhat R, Greenough A, et al
    An infant with persistent pulmonary hypertension of the newborn and congenital hypothyroidism.
    Case Rep Perinat Med. 2026;15:20260003.
    PubMed    
    Abstract available
    
    

45. ALTIT G, Sant'Anna G
    Artificial intelligence in neonatal hemodynamics: toward earlier and more reliable detection of pulmonary hypertension.
    Pediatr Res. 2026 Sep 11. doi: 10.1038/s41390-026-05461.
    PubMed    
    
    
    

46. WORKU E, Pittard M, Duffin S, Carey R, et al
    Awake venoarterial extracorporeal membrane oxygenation as a bridge to foetal maturation in severe pulmonary hypertension: a case report.
    Int J Obstet Anesth. 2026;68:105278.
    PubMed    
    Abstract available
    
    

47. MUNCHEL JK, Flashner BM, Imai R, Kholdani CA, et al
    Beyond IPF: Pulmonary Function Test Predictors of Echocardiographic Pulmonary Hypertension Across the Spectrum of ILD.
    Pulm Circ. 2026;16:e70400.
    PubMed    
    Abstract available
    
    

48. HERNANDEZ NV, Maestre MJ, Chavarria M, Munnangi P, et al
    Referral Patterns and Clinical Characteristics of Patients With Pulmonary Hypertension at a Comprehensive Care Center.
    Pulm Circ. 2026;16:e70399.
    PubMed    
    Abstract available
    
    

49. TSUGE S, Takaki J, Yoshinaga T, Fukui T, et al
    [Post-cardiac Surgery Pulmonary Hypertension Improved by High-flow Arteriovenous Shunts Closure].
    Kyobu Geka. 2026;79:407-410.
    PubMed    
    Abstract available
    
    

50. BANDYOPADHYAY D, Smith JE, Asif H, Uysal A, et al
    Pulmonary hypertension in interstitial lung disease: today's realities, tomorrow's possibilities.
    Minerva Med. 2026 Sep 10. doi: 10.23736/S0026-4806.26.09859.
    PubMed    
    Abstract available
    
    

51. LIN Y, Han J, Liu G, Cheng K, et al
    Integrated Metabolomic and Transcriptomic Analysis Suggests Potential Therapeutic Mechanism of Shengxian Decoction in Hypobaric Hypoxia-Induced Pulmonary Hypertension in SD Rats.
    Drug Des Devel Ther. 2026;20:603123.
    PubMed    
    Abstract available
    
    

52. ALOTAIBI M, Tang A, Sun N, Gurholt I, et al
    Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension.
    Circ Heart Fail. 2026 Sep 10:e014073. doi: 10.1161/CIRCHEARTFAILURE.125.014073.
    PubMed    
    Abstract available
    
    

53. GARRY JD, Brittain EL
    Disentangling Pulmonary Vascular Phenotypes in Group 2 Pulmonary Hypertension Using Bioactive Lipid Profiling.
    Circ Heart Fail. 2026 Sep 10:e014894. doi: 10.1161/CIRCHEARTFAILURE.126.014894.
    PubMed    
    
    
    

54. GATUZ MV, Okuno T, Tanaka T, Kai T, et al
    Phenotypes, periprocedural hemodynamic changes, and impact of pulmonary hypertension in patients undergoing mitral transcatheter edge-to-edge repair.
    Cardiovasc Interv Ther. 2026 Sep 9. doi: 10.1007/s12928-026-01346.
    PubMed    
    Abstract available
    
    

55. KUANG L, Huang EL, Zhang BY, Chen HJ, et al
    Long-term ambient air pollution exposure, metabolomic signatures, and incident pulmonary hypertension: A large prospective cohort study.
    Ecotoxicol Environ Saf. 2026;323:120778.
    PubMed    
    Abstract available
    
    

56. PU M
    Correlation between ACE2 and monocrotaline-induced pulmonary arterial hypertension in rats.
    Exp Lung Res. 2026;52:182-195.
    PubMed    
    Abstract available
    
    

57. YAMASHITA J, Ito R, Ikeda S, Hasegawa K, et al
    Invasive Management for Acute-on-Chronic Thromboembolic Pulmonary Hypertension: Feasibility and Clinical Outcomes in a Single-Center Cohort.
    Pulm Circ. 2026;16:e70407.
    PubMed    
    Abstract available
    
    

58. RODENBURG TC, Hoek LJO, Kan CV, Aman J, et al
    Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Disease without Pulmonary Hypertension: Prevalence and Clinical Impact in a Dutch Cohort.
    TH Open. 2026;10:a29386324.
    PubMed    
    Abstract available
    
    

59. ALLAM H, Fredman E, Kobayashi D, Aggarwal M, et al
    Transcatheter Sinus Venosus ASD Closure in Severe Pulmonary Hypertension.
    JACC Case Rep. 2026 Sep 1:110220. doi: 10.1016/j.jaccas.2026.110220.
    PubMed    
    Abstract available
    
    

60. WALIGORA M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, et al
    Early and long-term outcomes and their predictors in incident pulmonary arterial hypertension: Results from the Database of Pulmonary Hypertension in Poland (BNP-PL).
    Kardiol Pol. 2026 Sep 8. doi: 10.33963/v.phj.114700.
    PubMed    
    Abstract available
    
    

61. SONG S, Wu J, Yin M, Shi Y, et al
    Targeting Inflammation-Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension.
    Int J Nanomedicine. 2026;21:620348.
    PubMed    
    Abstract available
    
    

62. 
    [Chinese expert consensus on a standardized echocardiography procedure and right heart evaluation for pulmonary thromboembolism (2026 edition)].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:957-970.
    PubMed    
    Abstract available
    
    

63. PINTO S, Salvi de Souza G, Jeckel CMM, Bodanese LC, et al
    Role of PET imaging in evaluating right ventricular function and prognosis in pulmonary hypertension.
    Clinics (Sao Paulo). 2026;81:101101.
    PubMed    
    Abstract available
    
    

64. DONG F, Tanaka Y, Okamura K, Higa K, et al
    Right Ventricular Isovolumetric Relaxation Time is Associated with Pulmonary Vascular Load and Functional Limitation in Chronic Obstructive Pulmonary Disease.
    Int J Chron Obstruct Pulmon Dis. 2026;21:628505.
    PubMed    
    Abstract available
    
    

65. NAMAJIMA T, Ushijima R, Tanaka R
    Novel oblique dynamic chest radiography for retrocardiac pulmonary blood flow imaging in chronic thromboembolic pulmonary hypertension.
    Eur Heart J. 2026 Sep 7:ehag711. doi: 10.1093.
    PubMed    
    
    
    

66. WANG Q, Hao L, Cao W, Hu C, et al
    Burden dynamics of pulmonary arterial hypertension in China and the G20 aggregate: a comparative analysis based on the global burden of disease study 2023.
    Ann Med. 2026;58:2727194.
    PubMed    
    Abstract available
    
    

67. LYU Y, Tian L, Dai D, Xiang P, et al
    Diagnostic performance of the main pulmonary artery-to-ascending aorta diameter ratio for pulmonary hypertension defined by mean pulmonary arterial pressure in children with left-to-right shunt congenital heart disease.
    Quant Imaging Med Surg. 2026;16:735.
    PubMed    
    Abstract available
    
    

68. ASHRAF B, Hussain MU, Zahid A, Sohail F, et al
    Transition From Pulmonary to Gastrointestinal Hemorrhage: A Rare Case of Hematemesis in an Adolescent With Chronic Pulmonary Hypertension and Valvular Regurgitation.
    Clin Case Rep. 2026;14:e73480.
    PubMed    
    Abstract available
    
    

69. RAVNESTAD H, Ahmed S, Ostby CM, Gude E, et al
    The association between soluble ST2 and transplant-free survival in precapillary pulmonary hypertension.
    JHLT Open. 2026;14:100661.
    PubMed    
    Abstract available
    
    

70. ALNASSER TN, Hokmabadi A, Maiter A, Sharkey M, et al
    AI-based pulmonary artery to ascending aorta ratio on non-contrast CT for pulmonary hypertension: diameter vs. volume assessment.
    Eur Heart J Imaging Methods Pract. 2026;4:qyag146.
    PubMed    
    Abstract available
    
    

71. MOMOI M, Anzai A, Maeda T, Ikegami S, et al
    Progression of chronic thromboembolic pulmonary disease without pulmonary hypertension in a case with JAK2 V617F mutation.
    J Cardiol Cases. 2026;34:133-136.
    PubMed    
    Abstract available
    
    

72. KIZILOGLU HA, Yakar HI
    Combined Pulmonary Fibrosis and Emphysema: Clinicoradiological Parameters Associated with Fibrosis Patterns.
    J Coll Physicians Surg Pak. 2026;36:1120-1125.
    PubMed    
    Abstract available
    
    

73. XIE Y, Li J, Liao J, Meng H, et al
    beta-Sitosterol attenuates pulmonary arterial hypertension by activating the Nrf2-GPX4 axis to inhibit ferroptosis in pulmonary vascular cells.
    Biochem Pharmacol. 2026;253.
    PubMed    
    Abstract available
    
    

74. CAO Z, Meng L, Li Y, Zhou M, et al
    Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework.
    Int J Clin Pharm. 2026;48:1947-1956.
    PubMed    
    Abstract available
    
    

75. HAUSSMANN AJ, Chin AT, Wilhalme H, Volkmann ER, et al
    Interstitial lung disease in mixed connective tissue disease: Insights from an electronic health record-based retrospective cohort study.
    Semin Arthritis Rheum. 2026;80:153043.
    PubMed    
    Abstract available
    
    

76. RAGHUPATHY J, Teoh WS, Kanneganti A, Binte Abdul Kadir H, et al
    Clinical and autoantibody associations with malignancy in systemic sclerosis: a systematic review and meta-analysis.
    Rheumatology (Oxford). 2026;65:keag356.
    PubMed    
    Abstract available
    
    

77. NEMANIC TS, Fabella A
    Use of ambrisentan in the management of refractory pulmonary arterial hypertension following occlusion of a bidirectionally shunting patent ductus arteriosus in a dog.
    J Vet Cardiol. 2026;66:56-62.
    PubMed    
    Abstract available
    
    

78. YOSHINO I, Saji H, Suzuki H
    The lung-muscle metabolic axis: a proposed mechanism for post-resection systemic frailty.
    Surg Today. 2026;56:2111-2117.
    PubMed    
    Abstract available
    
    

79. TSUCHIDA K
    Clinical Applications of Ligand Traps Targeting Activin Type II Receptors.
    Antiinflamm Antiallergy Agents Med Chem. 2026;25:73-78.
    PubMed    
    Abstract available
    
    

80. ILLAHI D, Parrey AH, Ismail M
    Prevalence, Severity, and Pattern of Pulmonary Arterial Hypertension and Interstitial Lung Disease in Patients with Connective Tissue Disease.
    Curr Rheumatol Rev. 2026;22:e15733971388491.
    PubMed    
    Abstract available
    
    

81. FARBER HW, Chakinala MM, Hemnes AR, Chin KM, et al
    Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity.
    J Racial Ethn Health Disparities. 2026;13:4283-4295.
    PubMed    
    Abstract available
    
    

82. WONGWIEN P, Pussadhamma B, Kanjanawart S, Areesinpitak T, et al
    CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension.
    Br J Clin Pharmacol. 2026 Sep 18. doi: 10.1002/bcp.70826.
    PubMed    
    Abstract available
    
    

83. CHEN Y, Wang C, Lin Q, Chen J, et al
    Association of ACE2 gene polymorphisms with risk of pulmonary arterial hypertension in neonates with congenital heart disease.
    BMC Cardiovasc Disord. 2026;26:814.
    PubMed    
    Abstract available
    
    

84. AKIN A
    Sotatercept in Pediatric Pulmonary Hypertension: Promising Hemodynamic Findings, but Are We Extrapolating Too Far?
    Pediatr Cardiol. 2026 Sep 18. doi: 10.1007/s00246-026-04492.
    PubMed    
    Abstract available
    
    

85. PERACAULA M, Aguilar D, Vea A, Rodriguez C, et al
    Endothelial Cell Transcriptomics Reveal Activation of Ribosomal-related Pathways in Chronic Thromboembolic Pulmonary Hypertension.
    Arch Bronconeumol. 2026 Sep 18:S0300-2896(26)00329.
    PubMed    
    Abstract available
    
    

86. ALSUFYANI RH, Imran S, Mccullagh B, Hassan T, et al
    Riociguat as inpatient rescue therapy for acute decompensation of inoperable chronic thromboembolic pulmonary hypertension.
    BMJ Case Rep. 2026;19:e271552.
    PubMed    
    Abstract available
    
    

87. TAKEDA K, Shigeta A, Yamamoto K, Naito A, et al
    Prevalence and predictors of pulmonary hypertension in patients with progressive pulmonary fibrosis: A retrospective study.
    Respir Investig. 2026;64:101512.
    PubMed    
    Abstract available
    
    

88. FARINA N, Bellando Randone S, Jenssen-Bjorkekjaer H, Sanges S, et al
    Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study.
    Rheumatology (Oxford). 2026 Sep 18:keag516. doi: 10.1093.
    PubMed    
    Abstract available
    
    

89. XU Y, Pang X
    Mechanism of IH promoting pulmonary arterial hypertension through ROS-NLRP3 inflammasome mediated endothelial cell pyroptosis.
    Exp Lung Res. 2026;52:196-206.
    PubMed    
    Abstract available
    
    

90. PRESTES JP, de Oliveira VR, Zimmer A, Drosdowski D, et al
    Cardioprotective effects of melatonin in vitro and in two in vivo models of heart disease: Isoproterenol-induced cardiac injury and pulmonary hypertension.
    Toxicol Appl Pharmacol. 2026 Sep 17:118038. doi: 10.1016/j.taap.2026.118038.
    PubMed    
    Abstract available
    
    

91. WANG Y, Liang Q, Gao Y, Geng J, et al
    Malate-aspartate shuttle inactivation drives pulmonary hypertension through glucose carbon flux rewiring and alpha-ketoglutarate-dependent epigenetic remodeling.
    Redox Biol. 2026;97:104400.
    PubMed    
    Abstract available
    
    

92. SAM J, Spreuer T, Berger M, Yogeswaran A, et al
    Benchmarking AI Vibe Coding for Clinical Statistical Analysis: A Structured Evaluation in Pulmonary Hypertension Research.
    Stud Health Technol Inform. 2026;340:234-241.
    PubMed    
    Abstract available
    
    

93. ALLAHAM L, King B, Ali F, Gupta I, et al
    GLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge Gaps.
    Lung. 2026;204:68.
    PubMed    
    Abstract available
    
    

94. WU M, Zhang L, Wang X, Xu S, et al
    Routine-Data Nomogram for Estimating Pulmonary Hypertension Risk in Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    J Vis Exp. 2026;.
    PubMed    
    Abstract available
    
    

95. HE Y, Zhu Y, Lv Q, Wu H, et al
    NF-kappaB signaling as a critical inflammatory node in pulmonary arterial hypertension: from vascular remodeling to right heart failure.
    Front Immunol. 2026;17:1921908.
    PubMed    
    Abstract available
    
    

96. GIRALDO-SANDOVAL M, Guerrero-Pinedo FA, Herrera-Pena AM, Agrado-Torres JD, et al
    Clinical Outcomes of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Cohort Study From a Latin American Care Center.
    Pulm Circ. 2026;16:e70411.
    PubMed    
    Abstract available
    
    

97. WANG J, Zheng S, Yiminniyaze R, Zheng H, et al
    Association Between Serum Uric Acid and Pulmonary Hypertension in Takayasu Arteritis With Pulmonary Artery Involvement: A Cross-Sectional Study.
    Pulm Circ. 2026;16:e70393.
    PubMed    
    Abstract available
    
    

98. TAN X, Luo M, Ma R, Liu H, et al
    AI-based prediction of pulmonary hypertension in COPD patients with cor pulmonale using clinical and CT features.
    Front Med (Lausanne). 2026;13:1869175.
    PubMed    
    Abstract available
    
    

99. FERNANDEZ-RUIZ I
    Pulmonary artery denervation shows promising results for heart failure-related pulmonary hypertension.
    Nat Rev Cardiol. 2026 Sep 15. doi: 10.1038/s41569-026-01350.
    PubMed    
    
    
    

100. HE RX, Yang HM, Liu JR, Tang XL, et al
     [Etiological and clinical classification of pulmonary hypertension in children].
     Zhonghua Er Ke Za Zhi. 2026;64:1168-1172.
     PubMed    
     Abstract available
     
     

101. AMADO VM, Pereira MC, Correa RA, Campos FAFT, et al
     Brazilian guidelines for the pharmacological treatment of pulmonary hypertension. Official document of the Brazilian Thoracic Society based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.
     Respir Res Clin Pract. 2026;52:e20250528.
     PubMed    
     Abstract available
     
     

102. ZHANG R, Wu Y, Gong S, Jiang Q, et al
     Severe pulmonary hypertension due to chronic lung disease: Relevant hemodynamic criteria from a multicenter cohort study.
     Chin Med J (Engl). 2026 Sep 15. doi: 10.1097/CM9.0000000000004293.
     PubMed    
     
     
     

103. MCQUADE C, Davoudi D, Lajkosz K, Donahoe L, et al
     Differences in Chronic Pulmonary Embolism Burden in Chronic Thromboembolic Disease with and Without Pulmonary Hypertension.
     J Clin Med. 2026;15:6878.
     PubMed    
     Abstract available
     
     

104. LIU SC, Ku M, Mohnani P, Borse T, et al
     Group 3 Pulmonary Hypertension: Mechanistic Insights, Clinical Challenges, and Evolving Therapies.
     J Clin Med. 2026;15:6810.
     PubMed    
     Abstract available
     
     

105. FERRANTE M, Ali HJ, Hobbs G, Leiva O, et al
     The Current Landscape of Pulmonary Hypertension in Myeloproliferative Neoplasms.
     Cancers (Basel). 2026;18:2775.
     PubMed    
     Abstract available
     
     

106. CHOJNACKA K, Sibrecht G, Gruca-Stryjak K, Szczapa T, et al
     Severe Suprasystemic Refractory Pulmonary Hypertension in a Neonate with Stuve-Wiedemann Syndrome Associated with Biallelic LIFR Variants: Molecular Insights and a Neonatal Case Report.
     Int J Mol Sci. 2026;27:7824.
     PubMed    
     Abstract available
     
     

107. SINGH K, Ali M, G KK, Palmo T, et al
     Integrated Cytokine and Immune Cell Profiling Reveals a Distinct Immune Signature Associated with High-Altitude Pulmonary Edema.
     Int J Mol Sci. 2026;27:7787.
     PubMed    
     Abstract available
     
     

108. SAWCZAK F, Kukfisz A, Soloch A, Kurkiewicz-Sawczak K, et al
     Natriuretic Peptides as Predictors for the Diagnosis of Pulmonary Hypertension Secondary to Left Heart Disease and for the Assessment of Its Severity.
     Int J Mol Sci. 2026;27:7776.
     PubMed    
     Abstract available
     
     

109. FERRANTELLI S, Del Cuore A, Cassataro G, Dell'Ajra L, et al
     Artificial Intelligence and Multi-Omics Approaches in the Precision Management of Pulmonary Hypertension: From Early Diagnosis to Therapeutic Stratification.
     Int J Mol Sci. 2026;27:7763.
     PubMed    
     Abstract available
     
     

110. CHANG SA
     Pulmonary hypertension in pregnancy: hemodynamic challenges, maternal risk, and multidisciplinary management.
     J Cardiovasc Imaging. 2026;34:33.
     PubMed    
     Abstract available
     
     

111. OSADCHII AM, Zugurov IK, Simakova MA, Belyaninova IV, et al
     [Floating right atrial mass in a patient with suspected chronic thromboembolic pulmonary hypertension].
     Khirurgiia (Mosk). 2026;.
     PubMed    
     Abstract available
     
     

112. OSADCHII AM, Zugurov IK, Simakova MA, Moiseeva OM, et al
     [Early outcomes of controllable pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a single-centre experience at the Almazov National Medical Research Centre].
     Khirurgiia (Mosk). 2026;.
     PubMed    
     Abstract available
     
     

113. ALMEIDA SOUTO M, Baez M, Perri M, Zelaya de Leon N, et al
     Can a Multidisciplinary Team Change the Course of Chronic Thromboembolic Pulmonary Hypertension? Changes in Time to Diagnosis After PERT Implementation.
     Open Respir Arch. 2026;8:100663.
     PubMed    
     Abstract available
     
     

114. YEN TH, Isomura Y, Suzuki M, Huang WN, et al
     Baseline disease activity index and forced vital capacity predict clinically meaningful complications and mortality in systemic sclerosis.
     Rheumatology (Oxford). 2026;65:keag481.
     PubMed    
     Abstract available
     
     

115. POURDADASHI A, Eskandari P, Najafabadi ZG, Tajari A, et al
     Integrated transcriptomic and machine learning analysis identifies female-associated candidate biomarkers in Idiopathic pulmonary arterial hypertension.
     Comput Biol Chem. 2026;125:109276.
     PubMed    
     Abstract available
     
     

116. YEOM GE, Shin SH, Kim HS, Kim EK, et al
     Factors associated with short-term response after systemic corticosteroid treatment in invasively ventilated preterm infants.
     BMC Pediatr. 2026 Jun 29. doi: 10.1186/s12887-026-07119.
     PubMed    
     Abstract available
     
     

117. FUJII H, Isobe S, Tamura Y
     Hemodynamic improvement but worsening hypoxemia after balloon pulmonary angioplasty: severe eosinophilic asthma unmasked in CTEPH.
     BMC Pulm Med. 2026;26:409.
     PubMed    
     Abstract available
     
     

118. CHEN Z, Cai Z, Chen S, Xie L, et al
     DNA Methylation-Mediated Regulation of TAGLN2 Expression Promotes Pulmonary Arterial Hypertension.
     Arch Med Res. 2026;57:103434.
     PubMed    
     Abstract available
     
     

119. SHASHIKALA NV, Arun KM, Ashwini RC, Patil M, et al
     Pulmonary arterial hypertension in infancy: A case series.
     Trop Doct. 2026;56:720-722.
     PubMed    
     Abstract available
     
     

120. ZACHARIOUDAKI E, Trivyza MS, Papasotiriou M, Tsakas S, et al
     Endothelin: A Potential Universal Systemic Biomarker.
     Curr Med Chem. 2026;33:2909-2924.
     PubMed    
     Abstract available
     
     

121. YOKOMORI H, Ikeda N, Tsukagoshi Y, Waga S, et al
     Exercise Stress Echocardiographic Assessment of Exercise-Induced Pulmonary Hypertension in Patients with Chronic Thromboembolic Pulmonary Hypertension after Balloon Pulmonary Angioplasty.
     Am J Cardiol. 2026 Sep 13:S0002-9149(26)00573.
     PubMed    
     Abstract available
     
     

122. JAMES KS, Helms MN
     Unraveling the NO-sGC-cGMP Pathway in BPD-Associated Pulmonary Hypertension.
     Am J Physiol Heart Circ Physiol. 2026 Sep 8. doi: 10.1152/ajpheart.90017.2026.
     PubMed    
     
     
     

123. D'ALTO M, Cangiano N, Orlando A, Argiento P, et al
     Multicenter invasive validation of the Venous Excess Ultrasound Score (VExUS) in patients referred for pulmonary hypertension.
     Chest. 2026 Aug 29:S0012-3692(26)06526-8. doi: 10.1016/j.chest.2026.
     PubMed    
     Abstract available
     
     

124. WESSELS JN, Celant LR
     Brain Natriuretic Peptide-Guided Risk Stratification in Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy: A Foundation for Multimodal Assessment.
     Chest. 2026;170:657-658.
     PubMed    
     
     
     

125. KOGAMI M, Kato Y, Ito S, Uchida K, et al
     Mechanosensitive Stanniocalcin-1 Suppresses Pulmonary Artery Smooth Muscle Cell Proliferation and Attenuates Experimental Pulmonary Hypertension.
     Circ Res. 2026 Sep 9. doi: 10.1161/CIRCRESAHA.125.327869.
     PubMed    
     Abstract available
     
     

126. ZHANG J, Li Y, He M, Tan J, et al
     PUS7-Mediated Pseudouridylation of TGFBI Drives Vascular Remodeling in Pulmonary Hypertension.
     Circulation. 2026 Sep 1. doi: 10.1161/CIRCULATIONAHA.126.080714.
     PubMed    
     Abstract available
     
     

127. LYNCH PT, Makkapati S, George JC, Vaidya A, et al
     Left Circumflex Coronary-Pulmonary Arterial Collaterals in Chronic Thromboembolic Pulmonary Hypertension.
     Circulation. 2026;154:872.
     PubMed    
     
     
     

128. LACAVERA M, Asghar A, Ballard J, Bandla M, et al
     Pulmonary hypertension related to sleep-disordered breathing.
     Curr Opin Pulm Med. 2026 Sep 9. doi: 10.1097/MCP.0000000000001307.
     PubMed    
     Abstract available
     
     

129. GRYNBLAT J, Coulet F, Lacoste-Palasset T, Jais X, et al
     Beyond Heritable PAH: Pulmonary Hypertension in Genetic Syndromes.
     Eur Respir J. 2026 Sep 10:2600808. doi: 10.1183/13993003.00808-2026.
     PubMed    
     Abstract available
     
     

130. GHANI H, Pepke-Zaba J
     Reverse remodelling in chronic thromboembolic pulmonary hypertension: the right ventricular enigma continues.
     Eur Respir J. 2026;68:2601039.
     PubMed    
     
     
     

131. AERTS G, Willems L, Tielemans B, Muscogiuri E, et al
     Three-dimensional micro-CT analysis of vascular remodelling and vascular pruning in pulmonary arterial hypertension.
     Eur Respir J. 2026;68:2502118.
     PubMed    
     Abstract available
     
     

132. ERSBOLL MK, Kjaergaard J, Waidtlow K, Kober L, et al
     Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.
     J Heart Lung Transplant. 2026 Aug 31:S1053-2498(26)01987.
     PubMed    
     Abstract available
     
     

133. DADON Y, Mimouni FB, Arad I, Mendlovic J, et al
     Magnesium therapy in persistent pulmonary hypertension of the newborn: a scoping review.
     J Perinatol. 2026 Sep 10. doi: 10.1038/s41372-026-02893.
     PubMed    
     Abstract available
     
     

134. ZHANG H, Wang Q, Liang M, Chen X, et al
     Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension.
     N Engl J Med. 2026 Aug 30. doi: 10.1056/NEJMoa2609056.
     PubMed    
     Abstract available
     
     

135. IMERBTHAM T, Sriwantana T, Ngamjanyaporn P, Sotananusak T, et al
     Endothelial and platelet dysfunction in systemic sclerosis with pulmonary hypertension.
     PLoS One. 2026;21:e0357987.
     PubMed    
     Abstract available